2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10287
    Gosogliptin 869490-23-3 99.83%
    Gosogliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-IV).
    Gosogliptin
  • HY-10327
    GW-6604 452342-37-9 98.0%
    GW-6604 is an ALK5 inhibitor with an IC50 value of 140 nM for inhibiting its autophosphorylation, and can be used in the study of liver fibrosis.
    GW-6604
  • HY-12185
    BRD7389 376382-11-5 99.06%
    BRD7389 is a specific RSK family kinase inhibitor with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. BRD7389 is a small-molecule inducer of insulin expression in pancreatic α-cells.
    BRD7389
  • HY-12829
    SR-3306 1128096-91-2 99.0%
    SR-3306 is a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor. SR-3306 is a neuroprotective agent that can be used for the study of Parkinson's disease, ischemia/reperfusion (I/R) injury and obesity.
    SR-3306
  • HY-14471
    Cetilistat 282526-98-1 98.0%
    Cetilistat (ATL-962), an inhibitor of pancreatic lipase, acts as an effective anti-obesity agent. Cetilistat inhibits rat and human pancreatic lipase activity with IC50s of 54.8 nM, and 5.95 nM, respectively.
    Cetilistat
  • HY-14880
    Bavisant 929622-08-2 98.81%
    Bavisant (JNJ-31001074) is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H3 receptor. Bavisant can be used for attention-deficit hyperactivity disorder (ADHD) research.
    Bavisant
  • HY-14887
    Fedovapagon 347887-36-9 99.43%
    Fedovapagon (VA106483) is a selective and orally active vasopressin V2 receptor (V2R) agonist with an EC50 of 24 nM. Fedovapagon can be used in the research of nocturia.
    Fedovapagon
  • HY-15130
    DL-O-Phosphoserine 17885-08-4 ≥98.0%
    DL-O-Phosphoserine is a normal metabolite in human biofluids and is a mixture of phosphoserine with two stereochemical structures (D-type and L-type O-phospho-serine). O-phospho-L-serine is a competitive inhibitor of serine racemase and phagocytosis. O-phospho-L-serine inhibits the enzymatic reaction by competing with the active site of serine racemase, thereby affecting the production of D-serine. O-phospho-L-serine also mimics the phosphatidylserine head group, binds to the phosphatidylserine receptor, interferes with phagocytic signal transduction, and partially blocks the phagocytosis of apoptotic cells by cells. O-phospho-L-serin can be used in the research of retinal regeneration, bone repair, and insect growth and development.
    DL-O-Phosphoserine
  • HY-15344
    Ketone monoester 1208313-97-6
    Ketone monoester is an orally available ketone monoester that serves as a source of nutritional ketones. Ketone monoester increases plasma beta-hydroxybutyrate, acetoacetate, blood glucose, blood sodium, and blood creatinine levels in mouse models. Ketone monoester has the potential to improve athletic performance and endurance in animals. Ketone monoester partially prevents myasthenia in septic mice. Ketone monoester may also be used to study Parkinson's disease or diabetes.
    Ketone monoester
  • HY-19649
    Candoxatril 123122-55-4 99.56%
    Candoxatril is a neutral endopeptidase (NEP) inhibitor.
    Candoxatril
  • HY-19842
    GS-9667 618380-90-8 98.08%
    GS-9667 (CVT 3619), a novel N6-5'-substituted adenosine analog, is a selective, partial agonist of the A1 adenosine receptor (A1AdoR). GS-9667 binds to adipocyte membranes with high (KH=14 nM) and low (KL=5.4 μM) affinities. GS-9667 reduces cyclic AMP content and release of nonesterified fatty acids from epididymal adipocytes with IC50 values of 6 nM and 44 nM, respectively. GS-9667 inhibits lipolysis and has the potential for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA).
    GS-9667
  • HY-33914
    4-Hydroxymethylpyrazole 25222-43-9 ≥98.0%
    4-Hydroxymethylpyrazole is the primary metabolite of Fomepizole (HY-B0876) produced through hepatic oxidative metabolism. 4-Hydroxymethylpyrazole exhibits a plasma concentration that is positively correlated with the administered dosage of Fomepizole, and it demonstrates a relatively short half-life. 4-Hydroxymethylpyrazole demonstrates inhibitory effects on alcohol dehydrogenase (ADH) in both humans and monkeys, but its inhibition constant is significantly higher than that of Fomepizole, rendering its in vivo impact negligible.
    4-Hydroxymethylpyrazole
  • HY-35556
    9-Aminophenanthrene 947-73-9 99.86%
    9-Aminophenanthrene is a type of polycyclic aromatic amine compound, which can be used as a fluorescent labeling reagent for free fatty acids (FFA).
    9-Aminophenanthrene
  • HY-50159
    Glucagon receptor antagonist-3 202917-17-7 99.78%
    Glucagon receptor antagonist-3 is a highly potent glucagon receptor antagonist.
    Glucagon receptor antagonist-3
  • HY-50675
    GRA Ex-25 307983-31-9 99.07%
    GRA Ex-25 is an inhibitor of glucagon receptor, with IC50 of 56 and 55 nM for rat and human glucagon receptors, respectively.
    GRA Ex-25
  • HY-66054
    3-Methylpyrazole 1453-58-3 99.54%
    3-Methylpyrazole is used as a nitrification inhibitor of nitrification in soil.
    3-Methylpyrazole
  • HY-B0657
    Clodronic acid 10596-23-3 99.41%
    Clodronic acid (Clodronate) is an orally active bisphosphonate. Clodronic acid inhibits osteoclast-mediated bone resorption. Clodronic acid reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid is effective in the maintenance or improvement of bone mineral density. Clodronic acid can be used for the research of multiple myeloma and postmenopausal osteoporosis.
    Clodronic acid
  • HY-B1052
    Lofexidine hydrochloride 21498-08-8 99.72%
    Lofexidine hydrochloride (Baq-168) is an orally active agonist of the imidazoline I1 receptor (imidazoline I1 receptor) (Ki: 1.9 nM) and α2-adrenergic receptor (α2-adrenergic receptor). Lofexidine hydrochloride binds to the α2A-adrenergic receptor, reduces sympathetic outflow, lowers blood pressure, and exhibits vasoconstrictive effects. Lofexidine hydrochloride regulates the expression of c-fos and alleviates opioid withdrawal symptoms. Lofexidine hydrochloride is applicable to research on opioid addiction and withdrawal.
    Lofexidine hydrochloride
  • HY-B1069
    Molsidomine 25717-80-0 99.90%
    Molsidomine, a nitric oxide (NO) donor, is an orally active vasodilator agent. Molsidomine is a prodrug that can be rapidly metabolized in the liver to its active metabolite, Linsidomine (HY-101200). Molsidomine can be used for the study of angina pectoris, mental disorders and diabetic complications.
    Molsidomine
  • HY-B1435
    Moxisylyte hydrochloride 964-52-3 99.65%
    Moxisylyte (Thymoxamine) hydrochloride is a selective α1A-adrenergic receptor antagonist. Moxisylyte hydrochloride competitively antagonizes the activation mediated by norepinephrine. Moxisylyte hydrochloride relaxes penile cavernous smooth muscle and aids erectile function. Moxisylyte hydrochloride is applicable to research related to erectile dysfunction and multiple system atrophy.
    Moxisylyte hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity